Verona Pharma plc (VRNA) Financial Analysis & Valuation | Quarter Chart
Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (P... more
Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercial... more
Company facts
Reported company information and share structure.
Company
Share structure
| Market Cap | $72.68B | Exchange | NASDAQ |
| Sector | Healthcare | Industry | Biotechnology |
| Country | GB | CEO | David S. Zaccardelli |
| IPO Date | 2017-04-28 | CAGR | — |
| Employees | 209 | Website | www.veronapharma.com |
| Div. Yield | — | Payout Ratio | — |
| Buy Back Yield | 0.15% | Total Yield | 0.15% |
VRNA chart loading...
Key metrics
Reported fundamentals and market-derived technical indicators.
Fundamentals
Technicals
| EV | $7.91B | P/E | -102.8 | Forward P/E | — | PEG | — |
| P/S | 444.67 | P/B | 32.9 | P/CF | -930.9 | P/FCF | -7008.07 |
| Sales | $167.65M | Sales 1Y | — | Sales 3Y | 464.8% | Sales 5Y | — |
| EPS | $-1.04 | EPS 1Y | — | EPS 3Y | — | EPS 5Y | — |
| Sales QoQ | 27.3% | EPS QoQ | -166.67% | Sales QoQ Avg | — | EPS QoQ Avg | -69.59% |
| Gross Margin | 95.27% | Operating Margin | -7.92% | Profit Margin | -18.95% | ROCE | -2.48% |
| ROA | -5% | ROE | -13% | Altman Z Score | 109.91 | Piotroski Score | 3 |
| Current Ratio | 10.71 | Quick Ratio | 10.54 | Cash Ratio | 8.55 | Op. CF Ratio | 0.6 |
| Debt/Equity | 0.88 | Debt/Assets | 0.43 | Lt Debt/Equity | 0.87 | Lt Debt/Cap. | 0.47 |
| Intrst Cov. | -0.47 | Inventory Turnover | 0.9 | Asset Turnover | 0.29 | Receivables Turnover | 1.88 |
| Enterprise Value | $7.91B | P/E Ratio | -102.8 |
| Forward P/E | — | PEG Ratio | — |
| P/S Ratio | 444.67 | P/B Ratio | 32.9 |
| P/CF Ratio | -930.9 | P/FCF Ratio | -7008.07 |
| EPS | $-1.04 | EPS Growth 1Y | — |
| EPS Growth 3Y | — | EPS Growth 5Y | — |
| Revenue Growth 1Y | — | Gross Margin | 95.27% |
| Operating Margin | -7.92% | Profit Margin | -18.95% |
| ROE | -13% | ROA | -5% |
| ROCE | -2.48% | Current Ratio | 10.71 |
| Quick Ratio | 10.54 | Cash Ratio | 8.55 |
| Debt/Equity | 0.88 | Interest Coverage | -0.47 |
| Altman Z Score | 109.91 | Piotroski Score | 3 |
Verona Pharma plc (VRNA) valuation & financials
Verona Pharma plc (VRNA) has a market capitalization of $72.68B and trades at a price-to-earnings ratio of -102.8. It operates in the Healthcare sector (Biotechnology).
Compare with other Healthcare companies: Eli Lilly (LLY) · Johnson & Johnson (JNJ) · AbbVie (ABBV) · Merck (MRK) · UnitedHealth (UNH) · Roche (ROG.SW)